ABBV
AbbVie (NYSE: ABBV) announced that the European Commission approved AQUIPTA (atogepant) for the acute...
Article Summary
HOLD- AbbVie (NYSE: ABBV) announced that the European Commission approved AQUIPTA (atogepant) for the acute treatment of migraine in adults with or without aura, to be taken as needed.
- This approval is the second indication in the European Union for A QUIPTA, an oral calcitonin gene-related peptide receptor antagonist, with the drug now approved as both an acute treatment option for migraine attacks in adults and as a once-daily preventive option for adults with chronic or episodic migraine who experience four or more migraine days per month.
- Migraine is a prevalent neurological disease affecting roughly 14% of the global population with higher incidence in women than men, especially common among individuals aged 25 to 55, characterized by severe, throbbing headaches, cognitive impairment, sensitivity to light and sound, and nausea, resulting in significant limitations on daily activities.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 9.5% | 25% | 35.0 ptsBelow Screener (9.5%) - Weak growth |
| EPS Growth Next 5Y ? | 21.5% | 25% | 70.0 ptsGood (21.5%) - Solid outlook |
| Target Price Upside ? | 19.3% | 20% | 60.0 ptsModerate Upside (19.3%) - Target: $253.12 vs Current: $212.20 |
| Gross Margin % ? | 70.6% | 15% | 100.0 ptsExceptional (70.6%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -13.3% | 15% | 40.0 ptsMild Pullback (-13.3%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ABBV
- AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
- The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
- It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
- In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis.
- Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
- The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.